This guide has current information on reimbursement programs to help your patients alleviate the financial burden of their treatment.

"This framework is a practical, nonprescriptive tool, designed to summarize and organize essential elements of program evaluation."

"ASCO developed this 2018 statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education."

"This webinar contains practical information regarding use of biosimilar products, such as labeling, terminology, and pharmacy substitution and reviews the resources available to health care professionals about biosimilar and interchangeable products."

"Biosimilars are safe and effective medications for treating many illnesses such as arthritis and cancer. This website provides helpful information for patients about biosimilars."

"The FDA requires biosimilar and interchangeable biological products meet the Agency’s rigorous approval standards. This website provides information, resources, and educational opportunities for providers and patients."

"As healthcare professionals are at the forefront of patients’ care, it is vital that they have access to reliable information on these medicines: what they are and what scientific principles support their clinical development, approval and safety monitoring. This guide has therefore been prepared with the important objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars."

This quick video explains what biosimilars are and how they are being used to treat certain types of cancer.

"Sustainability in healthcare or clinical settings is affected by many organizational, financial, regulatory, and political factors. Understanding these factors can help stakeholders build capacity to sustain a clinical practice and position their efforts for long term success."

A document/communication tool developed by Penn Medicine that encompasses the most important information they felt needed to be relayed to patients prior to their next appointment at which time they would be receiving a biosimilar. This document is also sent through the patient portal.

"The present review aims to provide an overview of the biosimilars used in Europe and the USA, present their main benefits and challenges, and discuss their current and future roles in medical oncology."

This websites provides key elements of an evaluation plan, which can help guide your evaluation efforts.

"This course provides an understanding of biological products and biosimilar products and a description of FDA’s general approach to the development and approval of biosimilar products."

These tools and resources empower providers to proactively integrate financial health into the oncology care continuum and help patients gain access to high-quality care for a better quality of life.

"This white paper is a guide for all leaders interested in understanding the underlying psychology of change and leveraging its power to impact quality improvement efforts: to achieve breakthrough results, sustainably, at scale."